Phase 2 hit 72% ORR in RAS-mutant mCRC, but a licensor termination dispute now clouds whether Cardiff owns what it built

Cardiff Oncology is a clinical-stage company developing a targeted cancer drug for RAS-mutant metastatic colorectal cancer that is not yet approved, though a dispute with its licensor now raises questions about whether the company retains ownership of the asset.

Onvansertib, a PLK1 inhibitor added to standard FOLFIRI/bevacizumab, achieved 72.2% ORR versus 42.1% in RAS-mutated metastatic colorectal cancer, a cancer with historically poor outcomes. The thesis hinges on whether Cardiff retains clear legal title to onvansertib through its dispute with licensor Nerviano Medical Sciences. Cash of $34M funds only through Q3 2027, leaving enrollment of the 640-patient Phase 3 registrational trial contingent on additional financing.